Catherine Prady
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies, Cancer survivorship and care, Breast Cancer Treatment Studies
Most-Cited Works
- → Adjuvant Docetaxel for Node-Positive Breast Cancer(2005)951 cited
- → Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer(2016)60 cited
- → Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients(2017)46 cited
- → 379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study(2023)41 cited
- → Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study(2014)27 cited
- → Risk-Stratified Pathways for Cancer Survivorship Care: Insights from a Deliberative Multi-Stakeholder Consultation(2021)23 cited
- → Real-World Patient- and Caregiver-reported Outcomes in Advanced Breast Cancer(2018)22 cited
- → Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis(2017)20 cited
- → Collaborative governance in the Quebec Cancer Network: a realist evaluation of emerging mechanisms of institutionalization, multi-level governance, and value creation using a longitudinal multiple case study design(2019)20 cited
- → Prioritizing surgery during the COVID-19 pandemic: the Quebec guidelines(2021)18 cited